JPS5599189A - Modified uricase free from antigenicity and its preparation - Google Patents
Modified uricase free from antigenicity and its preparationInfo
- Publication number
- JPS5599189A JPS5599189A JP578779A JP578779A JPS5599189A JP S5599189 A JPS5599189 A JP S5599189A JP 578779 A JP578779 A JP 578779A JP 578779 A JP578779 A JP 578779A JP S5599189 A JPS5599189 A JP S5599189A
- Authority
- JP
- Japan
- Prior art keywords
- uricase
- antigenicity
- preparation
- free
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
PURPOSE: To prepare a modified uricase usable for treating patients with hyperuricemia, having a low or no antigenicity, by substituting 30% or more of amino groups in the uricase molecule with long-chain high polymer residues.
CONSTITUTION: Uricase is reacted with an 2-O-substituted-polyethylene glycol-4, 6-dichloro-s-triazine, e.g. 2-O-methoxypolyethylene glycol-4,6-dichloro-s-triazine, having a molecular weight ≥2,000 to give a modified uricase wherein 30% or more of amino groups in the uricase molecule are substituted by groups of the formula (R is water-soluble high polymer residue, e.g. O-methoxypolyethylene glycol residue, having a molecular weight ≥2,000).
COPYRIGHT: (C)1980,JPO&Japio
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP578779A JPS5599189A (en) | 1979-01-22 | 1979-01-22 | Modified uricase free from antigenicity and its preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP578779A JPS5599189A (en) | 1979-01-22 | 1979-01-22 | Modified uricase free from antigenicity and its preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS5599189A true JPS5599189A (en) | 1980-07-28 |
Family
ID=11620804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP578779A Pending JPS5599189A (en) | 1979-01-22 | 1979-01-22 | Modified uricase free from antigenicity and its preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5599189A (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57192435A (en) * | 1981-05-20 | 1982-11-26 | Toyobo Co Ltd | Modified polypeptide |
WO2006110819A2 (en) | 2005-04-11 | 2006-10-19 | Savient Pharmaceuticals, Inc. | Variant forms of urate oxidase and use thereof |
US7229810B2 (en) | 2001-06-28 | 2007-06-12 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of proteinases |
EP2158923A1 (en) | 1998-08-06 | 2010-03-03 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
US7811800B2 (en) | 2005-04-11 | 2010-10-12 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
US7927852B2 (en) | 1998-08-06 | 2011-04-19 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US8148123B2 (en) | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
EP2535347A1 (en) | 2002-09-30 | 2012-12-19 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US9534013B2 (en) | 2006-04-12 | 2017-01-03 | Horizon Pharma Rheumatology Llc | Purification of proteins with cationic surfactant |
US11598767B2 (en) | 2009-06-25 | 2023-03-07 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
-
1979
- 1979-01-22 JP JP578779A patent/JPS5599189A/en active Pending
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57192435A (en) * | 1981-05-20 | 1982-11-26 | Toyobo Co Ltd | Modified polypeptide |
US9885024B2 (en) | 1998-08-06 | 2018-02-06 | Duke University | PEG-urate oxidase conjugates and use thereof |
EP2158923A1 (en) | 1998-08-06 | 2010-03-03 | Mountain View Pharmaceuticals, Inc. | Peg-urate oxidase conjugates and use thereof |
US8921064B2 (en) | 1998-08-06 | 2014-12-30 | Mountain View Pharmaceuticals, Inc. | Method for purifying urate oxidase tetramers and octamers |
US7927589B2 (en) | 1998-08-06 | 2011-04-19 | Mountain View Pharmaceuticals, Inc. | PEG-urate oxidase conjugates and use thereof |
US7927852B2 (en) | 1998-08-06 | 2011-04-19 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
EP2316475A1 (en) | 1998-08-06 | 2011-05-04 | Mountain View Pharmaceuticals, Inc. | Isolated tetrameric uricase |
US8618267B2 (en) | 1998-08-06 | 2013-12-31 | Mountain View Pharmaceuticals, Inc. | PEG-urate oxidase conjugates and use thereof |
US8067553B2 (en) | 1998-08-06 | 2011-11-29 | Mountain View Pharmaceuticals, Inc. | PEG-urate oxidase conjugates and use thereof |
US7229810B2 (en) | 2001-06-28 | 2007-06-12 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of proteinases |
EP2535347A1 (en) | 2002-09-30 | 2012-12-19 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US8188224B2 (en) | 2005-04-11 | 2012-05-29 | Savient Pharmaceuticals, Inc. | Variant forms of urate oxidase and use thereof |
US9017980B2 (en) | 2005-04-11 | 2015-04-28 | Crealta Pharmaceuticals Llc | Variant forms of urate oxidase and use thereof |
US8148123B2 (en) | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
US8293228B2 (en) | 2005-04-11 | 2012-10-23 | Savient Pharmaceuticals Inc. | Variant form of urate oxidase and use thereof |
US8034594B2 (en) | 2005-04-11 | 2011-10-11 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
US8465735B2 (en) | 2005-04-11 | 2013-06-18 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
US8541205B2 (en) | 2005-04-11 | 2013-09-24 | Savient Pharmaceuticals, Inc. | Variant forms of urate oxidase and use thereof |
US7964381B2 (en) | 2005-04-11 | 2011-06-21 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
US7811800B2 (en) | 2005-04-11 | 2010-10-12 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
US8178334B2 (en) | 2005-04-11 | 2012-05-15 | Savient Pharmaceuticals, Inc. | Variant form of urate oxidase and use thereof |
EP2947145A1 (en) | 2005-04-11 | 2015-11-25 | Crealta Pharmaceuticals LLC | Variant forms of urate oxidase and use thereof |
US11781119B2 (en) | 2005-04-11 | 2023-10-10 | Horizon Therapeutics Usa, Inc. | Variant forms of urate oxidase and use thereof |
US9670467B2 (en) | 2005-04-11 | 2017-06-06 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
WO2006110819A2 (en) | 2005-04-11 | 2006-10-19 | Savient Pharmaceuticals, Inc. | Variant forms of urate oxidase and use thereof |
EP3321359A1 (en) | 2005-04-11 | 2018-05-16 | Crealta Pharmaceuticals LLC | Variant forms of urate oxidase and use thereof |
US9534013B2 (en) | 2006-04-12 | 2017-01-03 | Horizon Pharma Rheumatology Llc | Purification of proteins with cationic surfactant |
US11598767B2 (en) | 2009-06-25 | 2023-03-07 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
US11639927B2 (en) | 2009-06-25 | 2023-05-02 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy |
US11982670B2 (en) | 2009-06-25 | 2024-05-14 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0310321A3 (en) | Immunomodulatory azaspiranes | |
MD1233B1 (en) | Erythromycin derivatives, process for their preparation and pharmaceutical composition on base thereof | |
JPS55123648A (en) | Cold-setting composition | |
JPS5599189A (en) | Modified uricase free from antigenicity and its preparation | |
JPS55138393A (en) | Semisynthesis of insulin | |
PT79840B (en) | Process for the preparation of polipeptides with alpha-amilase inhibiting action and pharmaceutical compositions therewith | |
BR0007589A (en) | Cell proliferation inhibitors | |
ES8203391A1 (en) | Copolymers having bactericidal activity, process for the preparation thereof and pharmaceutical compositions therefrom | |
DK109180A (en) | PEPTIDES WITH UBIQUITIN SIMILAR ACTIVITY AND PROCEDURE FOR PREPARING THEREOF | |
ES2008962A6 (en) | New-quanidino-thiazol compounds, their preparation, and use as intermediates of famotidine process. | |
CA2111083A1 (en) | Novel peptides, their preparation and use | |
JPS55135590A (en) | Modified asparaginase and uricase and their preparation | |
UA41871C2 (en) | Derivatives of erythromycin, a process for the preparation thereof and a pharmaceutical composition based thereon | |
ES2001389A6 (en) | Substituted toluidines, process for their preparation, pharmaceutical compositions containing them and their use as gastric secretion inhibitors. | |
FI98815B (en) | Process for the preparation of new pharmacologically useful ester derivatives of bispilocarpic acid | |
CA2049837A1 (en) | Powder coating compositions | |
DE3361628D1 (en) | Substituted 5-phenylthio-6-amino-pyrimidinones, process for their preparation and their use, and preparations containing these compounds | |
JPS55138392A (en) | Semisynthesis of insulin | |
JPS5559151A (en) | Aminoacid derivative | |
DK8502611A (en) | ||
JPS5440894A (en) | Cinchona-alkaloid-acrylonitrile copolymer and its preparation | |
EP0309262A3 (en) | Novel salicylates, their salts, pharmaceutical compositions containing them and process for preparing same | |
JPS5371093A (en) | Benzothiepin derivs. and process for their preparation | |
JPS543021A (en) | Novel derivative of glutamic acid and its preparation | |
ES471606A2 (en) | Preparation of benzylidene derivatives |